Short Bowel Syndrome - Pipeline Review, H1 2016

Date: May 31, 2016
Pages: 62
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S7F55ECFCBAEN
Leaflet:

Download PDF Leaflet

Short Bowel Syndrome - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Short Bowel Syndrome - Pipeline Review, H1 2016’, provides an overview of the Short Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome
  • The report reviews pipeline therapeutics for Short Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Short Bowel Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Short Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Short Bowel Syndrome
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Short Bowel Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Short Bowel Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome Overview
Therapeutics Development
Pipeline Products for Short Bowel Syndrome - Overview
Pipeline Products for Short Bowel Syndrome - Comparative Analysis
Short Bowel Syndrome - Therapeutics under Development by Companies
Short Bowel Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Short Bowel Syndrome - Products under Development by Companies
Short Bowel Syndrome - Companies Involved in Therapeutics Development
Ardelyx, Inc.
Medgenics, Inc.
Naia Limited
Nutrinia Ltd.
OxThera AB
Sancilio & Company, Inc.
Shire Plc
Tasly Pharmaceutical Group Co., Ltd.
Zealand Pharma A/S
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GXG-8 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDGN-205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTRA-9620 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDX-98940 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SC-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teduglutide (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZP-1848 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Short Bowel Syndrome - Recent Pipeline Updates
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
Oct 20, 2015: Naia Rare Diseases a subsidiary of Naia, Receives Orphan Drug Designation From U.S. FDA For NB1001 For The Treatment Of Short Bowel Syndrome
Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Short Bowel Syndrome, H1 2016
Number of Products under Development for Short Bowel Syndrome - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Short Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2016
Short Bowel Syndrome - Pipeline by Medgenics, Inc., H1 2016
Short Bowel Syndrome - Pipeline by Naia Limited, H1 2016
Short Bowel Syndrome - Pipeline by Nutrinia Ltd., H1 2016
Short Bowel Syndrome - Pipeline by OxThera AB, H1 2016
Short Bowel Syndrome - Pipeline by Sancilio & Company, Inc., H1 2016
Short Bowel Syndrome - Pipeline by Shire Plc, H1 2016
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016
Short Bowel Syndrome - Pipeline by Zealand Pharma A/S, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Short Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2016
Short Bowel Syndrome - Dormant Projects, H1 2016
Short Bowel Syndrome - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, H1 2016
Number of Products under Development for Short Bowel Syndrome - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

Ardelyx, Inc.
Medgenics, Inc.
Naia Limited
Nutrinia Ltd.
OxThera AB
Sancilio & Company, Inc.
Shire Plc
Tasly Pharmaceutical Group Co., Ltd.
Zealand Pharma A/S
Skip to top


Short Bowel Syndrome - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 35 pages
Irritable Bowel Syndrome - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 67 pages
Frozen Shoulder Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Sjogren's Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages

Ask Your Question

Short Bowel Syndrome - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: